Medical Device CVD Guide: FDA Compliance & Best Practices

Independent security researchers routinely find vulnerabilities in connected medical devices, sometimes before the manufacturer does. What happens next determines whether that discovery becomes a coordinated fix or an uncoordinated public disclosure that puts patients and the company's reputation at risk simultaneously. CVD is the structured process that makes the first outcome the default one.

Why CVD matters beyond compliance

A device manufacturer without a CVD program does not stop researchers from finding vulnerabilities; it just removes the channel through which a researcher can report one responsibly. Researchers who cannot find a way to report a finding, or who fear legal retaliation for having found it, have historically defaulted to one of three paths: publishing without warning, selling the finding, or simply not reporting it at all. All three are worse for patient safety than a functioning intake channel that gets the report to the people who can fix it.

CVD also changes the tenor of the relationship. A researcher who submits through a documented, respectful process and receives acknowledgment, a realistic timeline, and eventual credit is far less likely to escalate to public disclosure out of frustration. Manufacturers who have run mature CVD programs for years consistently report that the volume of "hostile" disclosures drops once a legitimate channel exists, because most researchers who find medical device vulnerabilities are motivated by patient safety, not by extortion.

The FDA's expectations for CVD

The February 3, 2026 premarket cybersecurity guidance requires, under Section 524B, that manufacturers of cyber devices maintain a plan to identify and address postmarket cybersecurity vulnerabilities, including coordinated vulnerability disclosure. In practice, this means your premarket submission needs to describe:

• How external parties (researchers, hospital IT, other manufacturers) can report a suspected vulnerability.
• How reports are triaged, including a severity methodology.
• Expected remediation timelines by severity.
• How affected customers and, where applicable, the FDA and ISAO/ISAC partners are notified.
• How disclosure to the public is coordinated once a fix or mitigation is available.

Reviewers look for a described, repeatable process rather than a promise to "handle it case by case." A vague statement that the company "welcomes security research" without an intake mechanism, a triage SLA, or a named owner reads as unimplemented policy, and it is a common source of deficiency letters on cyber devices with network connectivity or wireless interfaces.

ISO/IEC 29147 and ISO/IEC 30111: the reference standards

Two ISO standards define the mechanics most mature CVD programs are built on:

• ISO/IEC 29147 (Vulnerability Disclosure) covers the external-facing side: how a manufacturer publishes a disclosure policy, provides an intake channel, communicates with the reporter, and eventually publishes advisories.
• ISO/IEC 30111 (Vulnerability Handling Processes) covers the internal side: how a report becomes a tracked issue, how it is triaged and prioritized, how a fix is developed and verified, and how the loop is closed.

Neither standard was written for medical devices specifically, but both map cleanly onto the FDA's postmarket expectations, and citing them by name in your submission narrative gives reviewers a recognized framework to check your process against, rather than inventing a way to evaluate a bespoke description.

Core components of a working CVD program

The intake process in practice

A functioning intake process is simpler than most manufacturers expect, but it needs to exist somewhere a researcher can actually find it. At minimum:

1. Publish a security contact, ideally via a security.txt file at your domain root and a dedicated page describing your disclosure policy in plain language.
2. State explicitly what is in scope, what response time to expect, and that good-faith research will not be met with legal threats.
3. Route incoming reports to a named owner, not a shared inbox that anyone can miss.
4. Log every report into the same tracking system used for internally discovered vulnerabilities, so severity and remediation decisions are made on a level playing field.

Verification, triage, and CVSS

Once a report is confirmed, severity scoring should use CVSS v3.1 or v4.0 as a starting point, then be adjusted for medical device context that a generic CVSS score does not capture: is the vulnerability reachable only with physical access to the device, does exploitation require credentials already restricted to clinical staff, and what is the worst-case clinical impact if it is exploited. This adjusted rating is what should actually drive your remediation timeline, and documenting the adjustment (not just the raw CVSS score) is what shows a reviewer you have applied judgment rather than run a scanner.

CVD output should feed the same triage pipeline as your automated CVE monitoring. A vulnerability reported by a researcher and a CVE surfaced by SBOM matching should both resolve into a VEX statement with the same rigor, not two disconnected processes with different standards of evidence.

Remediation timelines: patch versus notify

Not every reported vulnerability can or should be patched immediately, and the FDA does not expect instant patches for every finding. What it expects is a documented decision: patch now, patch in the next scheduled release with an interim mitigation communicated to users, or determine through analysis that the finding does not warrant remediation (documented the same way a "not affected" VEX justification would be). The timeline commitment should scale with clinical risk, and it should be written down in your postmarket vulnerability management plan before you need it, not improvised under pressure from a researcher's disclosure deadline.

The safe harbor provision

A safe harbor commitment, a public statement that researchers acting in good faith and within the stated scope will not face legal action, is one of the highest-leverage, lowest-cost elements of a CVD program. Without it, researchers who find a vulnerability in a device with an aggressive terms-of-service or anti-reverse-engineering clause have a strong incentive to stay anonymous or disclose without warning. With it, the same researcher has a documented reason to engage directly with the manufacturer first.

Working with security researchers

Treat an incoming report as a collaboration, not an incident to be contained. Acknowledge quickly, ask clarifying technical questions the way you would with an internal engineer, and give the researcher a realistic timeline rather than silence. Manufacturers who credit researchers publicly (with consent) in their advisories tend to see repeat, good-faith engagement from the same research community over time, which functions as an ongoing, informal extension of internal testing.

Common pitfalls

• No public intake channel, forcing researchers to route through general support, where reports get lost or misrouted.
• Legal threats as a first response, which reliably pushes a researcher toward public disclosure out of self-protection.
• No connection between CVD and the SBOM/VEX pipeline, resulting in duplicated triage work and inconsistent severity judgments.
• Undefined remediation timelines, leaving both the researcher and internal engineering guessing at urgency.
• Treating CVD as a one-time policy document rather than a running process with metrics: report volume, time to acknowledgment, time to remediation.

How Blue Goat Cyber approaches CVD program design

We build CVD programs as an operational process, not a policy page. That means standing up an intake channel that is actually discoverable, defining a triage methodology tied to CVSS and clinical risk, setting remediation SLAs that engineering can commit to, and wiring the whole pipeline into the same SBOM and VEX tooling used for internally discovered vulnerabilities, so a reviewer sees one coherent postmarket vulnerability management story rather than two disconnected ones. Where a CVD program needs to be stood up quickly ahead of a submission deadline, this work is scoped through FDA Premarket Cybersecurity Services; where the program needs to run continuously postmarket, it is delivered through Postmarket SBOM & VEX Monitoring.

Where this fits in the cluster

• VEX Documents for Medical Devices
• SBOM Vulnerability Management for Medical Devices
• Postmarket Cybersecurity Monitoring Program
• FDA 524B Cybersecurity Requirements Explained

Related from Blue Goat Cyber

• FDA Postmarket Cybersecurity Services
• Postmarket SBOM & VEX Monitoring
• FDA Premarket Cybersecurity Services

FAQ

What is a coordinated vulnerability disclosure (CVD) program for medical devices?

A CVD program is the documented process by which a manufacturer receives vulnerability reports from external parties, typically independent security researchers, triages and verifies them, develops and validates a remediation, and coordinates public disclosure with the reporter once a fix or mitigation is available. For medical devices, it is one required element of the postmarket vulnerability management plan expected under Section 524B, and it is commonly built on ISO/IEC 29147 for the disclosure side and ISO/IEC 30111 for the internal handling side.

What does the FDA require for medical device vulnerability disclosure?

The FDA's February 3, 2026 premarket guidance requires cyber device manufacturers to describe a plan for identifying and addressing postmarket vulnerabilities, which includes a coordinated vulnerability disclosure process. Reviewers expect specifics: a described intake mechanism, a triage and severity methodology, remediation timelines, and a process for notifying affected users and, where applicable, the FDA. A general statement of willingness to work with researchers, without a described process, is typically insufficient.

How do I report a security vulnerability in a medical device?

If you are a researcher, check the manufacturer's website for a published security contact, a security.txt file, or a disclosure policy page. If none exists, many manufacturers still accept reports through general support channels or via ISAOs such as H-ISAC. If a manufacturer has no visible process at all, CISA's coordinated disclosure process can serve as an intermediary. Manufacturers should not rely on this fallback; publishing a clear, dedicated channel is the expected baseline.

What is the difference between CVD and a bug bounty program in healthcare?

CVD is a disclosure and handling process; it defines how a report is received, triaged, and resolved, and it does not require paying researchers. A bug bounty program is a specific incentive structure, typically financial rewards for qualifying findings, layered on top of a disclosure process. Most medical device manufacturers need a functioning CVD program as a baseline; a bug bounty is an optional enhancement that some device makers adopt once their CVD process and internal remediation capacity are mature enough to handle increased report volume.

How long do medical device manufacturers have to disclose a vulnerability?

There is no single fixed FDA deadline that applies to every vulnerability. Manufacturers are expected to set and follow their own remediation timelines, scaled to severity and clinical risk, as documented in their postmarket vulnerability management plan. For vulnerabilities that pose a significant risk to patient safety, the FDA expects prompt action and, in relevant cases, coordination with CISA and ISAO partners; delays that are inconsistent with a manufacturer's own stated policy, or that leave a known, exploitable, high-severity issue unaddressed for an extended period, are the pattern most likely to draw regulatory scrutiny.

Sources & primary references

• Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (FDA, February 3, 2026 final guidance)
• ISO/IEC 29147:2018 Information technology - Security techniques - Vulnerability disclosure
• ISO/IEC 30111:2019 Information technology - Security techniques - Vulnerability handling processes
• CISA Coordinated Vulnerability Disclosure Process